Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, has designed the helical metal nanostructures to mediate the manipulation of the chirality of drug molecules.
Scientists from Hong Kong Baptist University (HKBU) have developed a novel technique that can produce pure therapeutic drugs without the associated side effects.
The approach, which uses a nanostructure fabrication device, can manipulate the chirality of drug molecules by controlling the direction a substrate is rotated within the device, thus eliminating the possible side effects that can arise when people take drugs containing molecules with the incorrect chirality.
Published in the renowned international scientific journal Nature Chemistry, the research findings pave the way towards the mass production of purer, cheaper and safer drugs that can be made in a scalable and more environmentally-friendly way.
Control of molecular chirality improves drug safety
Many chemical molecules have two configurations, or chiral versions, that are mirror images of each other. While sharing the same molecular formula, the two chiral versions have different arrangements of their constituent atoms in space. The two versions of the molecules are characterised by left-handed and right-handed chiral configurations like human hands. Molecules with “left-handed” and “right-handed” chirality can have totally different biochemical effects.
More than half of the therapeutic drugs are made up of equal amounts of left-handed and right-handed chiral molecules, commonly known as “racemates”; one can cure specific diseases, but the other may have adverse effects. Separating and producing molecules with only the chiral arrangement (known as a single enantiomer) responsible for the therapeutic effects can help to produce drugs with improved safety and efficacy.
Macro-scale control of molecular chirality
In general, molecules have an extremely small size ranging from one-millionth to one hundred-thousandth of the diameter of a human hair. It is therefore extremely challenging to selectively produce one of the two chiral molecule versions using “macro-scale” control (i.e. the dimensional scale that can be seen using the naked eye and operated by hand). To produce single-enantiomer drugs, chemists have overwhelmingly used molecules called “chiral ligands” to effectively control the molecular chirality of drugs in the laboratory or industry at the molecular scale, a process called asymmetric synthesis. However, the existing technologies for producing single-enantiomer drugs are composed of complicated procedures, which are expensive and environmentally-unfriendly.
Dr Jeffery Huang Zhifeng, Associate Professor in the Department of Physics at HKBU, and his research team devised a novel approach to manipulating molecular chirality through macro-scale control in collaboration with Sichuan University, Guangxi Medical University and the Southern University of Science and Technology. It involves mediating the manipulation with helical metal nanostructures (i.e. metal nanohelices) that are in the shape of a helical spring, and they have a characteristic size of one-thousandth of the diameter of a human hair.
Direction of rotation determines molecular chirality
The research team fabricated the metal nanohelices using a nanofabrication technique called glancing angle deposition (GLAD). Silver and copper were deposited onto a supporting substrate that was rotated clockwise and counterclockwise to fabricate the right-handed and left-handed metal nanohelices, respectively.
The research team then used ultraviolet light to induce a chemical reaction. This caused 2-anthracenecarboxylic acid (AC) molecules adsorbing on the metal nanohelices to undergo the chemical reaction and form chiral molecular products, which are similar to some chiral drugs. When AC was attached to the surface of the right-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “right-handed” chiral molecular products. By the same token, when AC was adsorbed on the surface of the left-handed metal nanohelices and exposed to ultraviolet light, it preferentially produced “left-handed” chiral molecular products. In other words, the chirality of the molecular product can be reliably determined by the chirality of the metal nanohelices, which is controlled by the direction of substrate rotation.
The research demonstrates that controlling the direction of substrate rotation at a macroscopic level can conveniently manipulate molecular chirality. This is an unprecedented application of the macro-scale method (through the control of the rotation direction of a 4-inch substrate holder) to manipulate chirality at the molecular-scale (chiral molecular products in the range of one-billionth of a metre).
Green approach to reducing drug side effects
“Our success in manipulating molecular chirality through macroscopic engineering allows the convenient synthesis of drugs in single-enantiomer forms with only left- or right-handedness. Hence, it will help get rid of the adverse, sometimes fatal, side effects of many therapeutic drugs,” said Dr Huang.
The use of chiral ligands in the conventional method of asymmetric synthesis is inevitable, and it may cause pollution to enter the environment. In contrast, in this novel approach the metal nanohelices can be used repeatedly to produce single-enantiomer drugs without the use of chiral ligands. As a result, it paves the way towards the mass production of affordable therapeutic drugs that are made in a scalable manner with recyclable materials.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pure therapeutic drug production
- Current Understanding and Management of Giant Cell Arteritis and Polymyalgia Rheumatica
We still do not know why there is vascular involvement in GCA as opposed to pure PMR. One of the major ... will lead to the development of new therapeutic targets and therapies.
- Best CBD Gummies
u0009 Who Should Avoid Pure Balance CBD Gummies? While it’s only one CBD gummy per serving, the trace amounts of THC could potentially result in a positive drug test. The THC is within the legal ...
- Best CBD Oil to Review
Some companies use organic and pure products, while others focus on ... Eight lab tests are completed during the production process to ensure that users get exactly what the company advertises.
- Open Book Extracts Partners with Nalu Bio to Commercialize Synthetic THCV and Rare Cannabinoids
Open Book Extracts (OBX), a total solution provider for high quality cannabinoid ingredients, concept-to-market formulation services, and finished goods manufacturing, announced today an R&D and ...
- Best CBD Brands on the Market
Farm Bill, which President Trump signed into law, boosted the CBD market. It is now officially lawful to cultivate industrial hemp wherever you desire in the US due to this legislation.
Go deeper with Google Headlines on:
Pure therapeutic drug production
Go deeper with Bing News on:
- Ascletis announces FDA clearance of oral drug to conduct study in mild to moderate COVID-19 patients
A randomized, placebo-controlled study in mild to moderate COVID-19 patients has been approved by the US Food and Drug Administration (FDA).
- Verrica Pharmaceuticals receives $8M trigger payment from Japanese product development partner
Verrica Pharmaceuticals received an $8 million payment this week from its product development partner in Japan after a provision in their 2021 licensing deal kicked in.
- U.S. Prescription Drug Market Lacks Certain Competitive Features: Case Of Biosimilars
A regularly heard talking point is that follow-on drugs, such as biosimilars and generics, will bring down prices through competition. But, they don’t invariably do so. PBMs may favor more expensive ...
- Despite $5B sales for Keytruda, Merck hits two PhIII snags as it continues to build its multibillion-dollar drug
Continuing on its quest to grow Keytruda’s blockbuster status ahead of a 2028 patent cliff, Merck reported today that Keytruda has missed in two indications — as a first-line therapy in combination ...
- New recall alert: Erectile dysfunction drugs found hidden in another supplement
Ultra Supplement issued a recall for a Sustango supplement that contains a hidden erectile dysfunction drug that can be dangerous.